Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC.
Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC. J Thorac Oncol. 2024 Mar 08.
PMID: 38461929
Radiotherapy Enhances Metastasis Through Immune Suppression by inducing PD-L1 and MDSC in distal sites.
Radiotherapy Enhances Metastasis Through Immune Suppression by inducing PD-L1 and MDSC in distal sites. Clin Cancer Res. 2024 Mar 01.
PMID: 38427437
Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study.
Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study. J Thorac Oncol. 2024 02; 19(2):285-296.
PMID: 37797733
What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer?
What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer? Ther Adv Med Oncol. 2023; 15:17588359231198446.
PMID: 37720499
Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial.
Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial. J Thorac Oncol. 2023 12; 18(12):1731-1742.
PMID: 37597750
Epstein-Barr Virus DNA Screening in Asymptomatic People without Known Nasopharyngeal Cancer.
Epstein-Barr Virus DNA Screening in Asymptomatic People without Known Nasopharyngeal Cancer. NEJM Evid. 2023 Jul; 2(7):EVIDe2300077.
PMID: 38320171
Early-Stage Lung Cancer: Using Circulating Tumor DNA to Get Personal.
Early-Stage Lung Cancer: Using Circulating Tumor DNA to Get Personal. J Clin Oncol. 2023 09 01; 41(25):4093-4096.
PMID: 37352477
Using a Clinically Interpretable End Point Composed of Multiple Outcomes to Evaluate Totality of Treatment Effect in Comparative Oncology Studies.
Using a Clinically Interpretable End Point Composed of Multiple Outcomes to Evaluate Totality of Treatment Effect in Comparative Oncology Studies. JAMA Netw Open. 2023 06 01; 6(6):e2319055.
PMID: 37342044
A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer.
A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer. Ann Oncol. 2023 08; 34(8):714-722.
PMID: 37182801
Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non-small-cell lung cancer.
Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non-small-cell lung cancer. Future Oncol. 2023 Mar; 19(8):549-557.
PMID: 36815433